Gsa Capital Partners LLP Celldex Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 16,114 shares of CLDX stock, worth $414,774. This represents 0.04% of its overall portfolio holdings.
Number of Shares
16,114
Previous 5,533
191.23%
Holding current value
$414,774
Previous $205,000
167.32%
% of portfolio
0.04%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding CLDX
# of Institutions
205Shares Held
67.2MCall Options Held
1.55MPut Options Held
736K-
Wellington Management Group LLP Boston, MA9.24MShares$238 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$121 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$99.6 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$89 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$85.8 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.2B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...